Nilotinib [aka Tasigna] is a novel tyrosine kinase inhibitor that inhibits BCR-ABL [30]–[35], c-KIT and PDGFRα approved to treat CML or GIST patients, especially those showing imatinib-resistance or -intolerance [30]–[33]. The gene discussed is ABL1; the disease is gastrointestinal stromal tumor.